Skip to main content
. Author manuscript; available in PMC: 2022 Jan 20.
Published in final edited form as: Aliment Pharmacol Ther. 2020 Oct 21;52(11-12):1658–1675. doi: 10.1111/apt.16119

Figure 3:

Figure 3:

Nonresponder imputation analysis of corticosteroid-free symptomatic remission through Week 92†, ‡, §, ¶, ††, ‡‡ for all patients randomized to ustekinumab in the maintenance study (intent-to-treat population)